[
  {
    "ts": "2026-01-12T15:18:07+00:00",
    "headline": "JPM Preannouncements Take Their Toll As Alnylam Slides, Tempus, Day One Pop",
    "summary": "Alnylam stock slipped Monday after its fourth-quarter preannouncement ahead of the J.P. Morgan Healthcare Conference.",
    "url": "https://www.investors.com/news/technology/alnylam-preannouncement-biotech-companies-jpm/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "46871d11-8f1b-3c57-8fe7-97bc22a117a0",
      "content": {
        "id": "46871d11-8f1b-3c57-8fe7-97bc22a117a0",
        "contentType": "STORY",
        "title": "JPM Preannouncements Take Their Toll As Alnylam Slides, Tempus, Day One Pop",
        "description": "",
        "summary": "Alnylam stock slipped Monday after its fourth-quarter preannouncement ahead of the J.P. Morgan Healthcare Conference.",
        "pubDate": "2026-01-12T15:18:07Z",
        "displayTime": "2026-01-12T15:18:07Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/46871d11-8f1b-3c57-8fe7-97bc22a117a0/jpm-preannouncements-take.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/58e9316fa9c62395844afd14bb72bd19",
          "originalWidth": 1065,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zH7azFdDXv8e5vYEYm7z1Q--~B/aD02MDA7dz0xMDY1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/58e9316fa9c62395844afd14bb72bd19.cf.webp",
              "width": 1065,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XpSqX7kq1txWcXI3OMAMZw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/58e9316fa9c62395844afd14bb72bd19.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/alnylam-preannouncement-biotech-companies-jpm/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALNY"
            },
            {
              "symbol": "TEM"
            },
            {
              "symbol": "APLS"
            },
            {
              "symbol": "DAWN"
            },
            {
              "symbol": "JPM"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "IONS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-12T14:41:00+00:00",
    "headline": "CD22 Targeted Therapies Market Research Report 2025-2026: Opportunities Lie in Developing Precise CD22 Targeted Therapies for Blood Cancers, with Over 20 Ongoing Clinical Trials",
    "summary": "The main market opportunities lie in developing precise CD22 targeted therapies for blood cancers, with over 20 ongoing clinical trials. Innovative technologies like TALEN® are enhancing cell-based therapies. Key players like Pfizer and emerging biotechs are driving advancements, creating growth prospects in this evolving sector.Dublin, Jan. 12, 2026 (GLOBE NEWSWIRE) -- The \"CD22 Targeted Therapies Market, Approved Drug Sales, Technology Platforms & Clinical Trials Insight 2026\" report has been",
    "url": "https://finance.yahoo.com/news/cd22-targeted-therapies-market-research-144100921.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "b012d38a-caa6-3035-a669-9b3231946424",
      "content": {
        "id": "b012d38a-caa6-3035-a669-9b3231946424",
        "contentType": "STORY",
        "title": "CD22 Targeted Therapies Market Research Report 2025-2026: Opportunities Lie in Developing Precise CD22 Targeted Therapies for Blood Cancers, with Over 20 Ongoing Clinical Trials",
        "description": "",
        "summary": "The main market opportunities lie in developing precise CD22 targeted therapies for blood cancers, with over 20 ongoing clinical trials. Innovative technologies like TALEN® are enhancing cell-based therapies. Key players like Pfizer and emerging biotechs are driving advancements, creating growth prospects in this evolving sector.Dublin, Jan. 12, 2026 (GLOBE NEWSWIRE) -- The \"CD22 Targeted Therapies Market, Approved Drug Sales, Technology Platforms & Clinical Trials Insight 2026\" report has been",
        "pubDate": "2026-01-12T14:41:00Z",
        "displayTime": "2026-01-12T14:41:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cd22-targeted-therapies-market-research-144100921.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cd22-targeted-therapies-market-research-144100921.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-12T11:24:00+00:00",
    "headline": "AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations",
    "summary": "AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings target and the FDA flipped its position on a cell therapy from Atara.",
    "url": "https://www.biopharmadive.com/news/abbvie-buys-into-pd-1vegf-sweepstakes-alnylam-and-vertex-set-expectations/809312/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "0bde043c-d553-3ccd-bf4d-18cae76c848c",
      "content": {
        "id": "0bde043c-d553-3ccd-bf4d-18cae76c848c",
        "contentType": "STORY",
        "title": "AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations",
        "description": "",
        "summary": "AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings target and the FDA flipped its position on a cell therapy from Atara.",
        "pubDate": "2026-01-12T11:24:00Z",
        "displayTime": "2026-01-12T11:24:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YSECyFvzK8sIEiUW4LIicA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/heEgXBvKL8Y58FXAXGaXPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/abbvie-buys-into-pd-1vegf-sweepstakes-alnylam-and-vertex-set-expectations/809312/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-buys-pd-1-vegf-112400265.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "ALNY"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "BEAM"
            },
            {
              "symbol": "ATRA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-12T16:38:00+00:00",
    "headline": "‘Biotech Super Bowl’ Lands With a Thud. Stocks Slide on Lack of Deal News.",
    "summary": "Monday is the first day of  J.P. Morgan’s  annual healthcare investor conference, which draws thousands of investors, analysts, and executives to San Francisco each year.  There is ample precedent: Last year,  Johnson & Johnson  announced a $14.6 billion deal to acquire Intra-Cellular Therapeutics on the first day of the gathering.  The Wall Street Journal reported last week that Merck was in talks to buy the biotech Revolution Medicines for roughly $30 billion, but as of late morning, no such agreement had been announced.",
    "url": "https://www.barrons.com/articles/biotech-stocks-chase-conference-b9cab762?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "b75019f7-5087-30b3-a925-6f9de1cc8a35",
      "content": {
        "id": "b75019f7-5087-30b3-a925-6f9de1cc8a35",
        "contentType": "STORY",
        "title": "‘Biotech Super Bowl’ Lands With a Thud. Stocks Slide on Lack of Deal News.",
        "description": "",
        "summary": "Monday is the first day of  J.P. Morgan’s  annual healthcare investor conference, which draws thousands of investors, analysts, and executives to San Francisco each year.  There is ample precedent: Last year,  Johnson & Johnson  announced a $14.6 billion deal to acquire Intra-Cellular Therapeutics on the first day of the gathering.  The Wall Street Journal reported last week that Merck was in talks to buy the biotech Revolution Medicines for roughly $30 billion, but as of late morning, no such agreement had been announced.",
        "pubDate": "2026-01-12T16:38:00Z",
        "displayTime": "2026-01-12T16:38:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/b75019f7-5087-30b3-a925-6f9de1cc8a35/%E2%80%98biotech-super-bowl%E2%80%99-lands.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/8ebdb690c83f7dcd8efc0f89134f191d",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BHJPDjWZKaPfXg5a3nUTWQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/8ebdb690c83f7dcd8efc0f89134f191d.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qa7w9DeR_tRxUp5wVzRzPw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/8ebdb690c83f7dcd8efc0f89134f191d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/biotech-stocks-chase-conference-b9cab762?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "XBI"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "JPM"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-12T18:37:02+00:00",
    "headline": "JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won",
    "summary": "Alnylam stock slipped Monday after its fourth-quarter preannouncement ahead of the J.P. Morgan Healthcare Conference.",
    "url": "https://www.investors.com/news/technology/alnylam-preannouncement-biotech-companies-jpm/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "46871d11-8f1b-3c57-8fe7-97bc22a117a0",
      "content": {
        "id": "46871d11-8f1b-3c57-8fe7-97bc22a117a0",
        "contentType": "STORY",
        "title": "JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won",
        "description": "",
        "summary": "Alnylam stock slipped Monday after its fourth-quarter preannouncement ahead of the J.P. Morgan Healthcare Conference.",
        "pubDate": "2026-01-12T18:37:02Z",
        "displayTime": "2026-01-12T18:37:02Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/46871d11-8f1b-3c57-8fe7-97bc22a117a0/jpm-preannouncements-why.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/58e9316fa9c62395844afd14bb72bd19",
          "originalWidth": 1065,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zH7azFdDXv8e5vYEYm7z1Q--~B/aD02MDA7dz0xMDY1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/58e9316fa9c62395844afd14bb72bd19.cf.webp",
              "width": 1065,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XpSqX7kq1txWcXI3OMAMZw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/58e9316fa9c62395844afd14bb72bd19.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/alnylam-preannouncement-biotech-companies-jpm/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ALNY"
            },
            {
              "symbol": "DAWN"
            },
            {
              "symbol": "TEM"
            },
            {
              "symbol": "APLS"
            },
            {
              "symbol": "IRTC"
            },
            {
              "symbol": "SRPT"
            },
            {
              "symbol": "JPM"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-12T18:08:18+00:00",
    "headline": "Tempus AI's Pharma Momentum Accelerates",
    "summary": "Contract value passes $1.1 billion milestone",
    "url": "https://finance.yahoo.com/news/tempus-ais-pharma-momentum-accelerates-180818076.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "85ac4bd2-efe2-3f01-adfd-cada976dde73",
      "content": {
        "id": "85ac4bd2-efe2-3f01-adfd-cada976dde73",
        "contentType": "STORY",
        "title": "Tempus AI's Pharma Momentum Accelerates",
        "description": "",
        "summary": "Contract value passes $1.1 billion milestone",
        "pubDate": "2026-01-12T18:08:18Z",
        "displayTime": "2026-01-12T18:08:18Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/f59527b0d156b3bd2c9001300b62b795",
          "originalWidth": 3427,
          "originalHeight": 2263,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iP6UfZGBZGVTwO_16QJRfQ--~B/aD0yMjYzO3c9MzQyNzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/f59527b0d156b3bd2c9001300b62b795.cf.webp",
              "width": 3427,
              "height": 2263,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YLvDHMnsi9kcSTsCJp81Ew--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/f59527b0d156b3bd2c9001300b62b795.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/tempus-ais-pharma-momentum-accelerates-180818076.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tempus-ais-pharma-momentum-accelerates-180818076.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TEM"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-12T16:20:00+00:00",
    "headline": "MDGL Secures Exclusive Global Right for MASH Treatment From PFE",
    "summary": "Madrigal Pharmaceuticals obtains global rights to Pfizer's ervogastat. It intends to pair it with Rezdiffra to advance combination therapies for MASH.",
    "url": "https://finance.yahoo.com/news/mdgl-secures-exclusive-global-mash-162000787.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "3048d811-fc2e-3421-8083-6ac4fe9cfde5",
      "content": {
        "id": "3048d811-fc2e-3421-8083-6ac4fe9cfde5",
        "contentType": "STORY",
        "title": "MDGL Secures Exclusive Global Right for MASH Treatment From PFE",
        "description": "",
        "summary": "Madrigal Pharmaceuticals obtains global rights to Pfizer's ervogastat. It intends to pair it with Rezdiffra to advance combination therapies for MASH.",
        "pubDate": "2026-01-12T16:20:00Z",
        "displayTime": "2026-01-12T16:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EzN04L.MG5n2SiOn76bXjg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1EIdoTL1xBchT1nrSboC2Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/41b7bdd28f63138df08f17b665d3589a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/mdgl-secures-exclusive-global-mash-162000787.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/mdgl-secures-exclusive-global-mash-162000787.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MDGL"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-12T18:35:32+00:00",
    "headline": "Tempus Shares Jump After Strong Preliminary 2025 Results",
    "summary": "Investors Eye 2026 Guidance as Tempus AI Tops $1.1B in Contract Value",
    "url": "https://finance.yahoo.com/news/tempus-shares-jump-strong-preliminary-183532772.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "499a3594-e9d6-3fd4-93a4-f477fe21e7fd",
      "content": {
        "id": "499a3594-e9d6-3fd4-93a4-f477fe21e7fd",
        "contentType": "STORY",
        "title": "Tempus Shares Jump After Strong Preliminary 2025 Results",
        "description": "",
        "summary": "Investors Eye 2026 Guidance as Tempus AI Tops $1.1B in Contract Value",
        "pubDate": "2026-01-12T18:35:32Z",
        "displayTime": "2026-01-12T18:35:32Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/433110cf9f928b1f27e41465a8ce0b49",
          "originalWidth": 3000,
          "originalHeight": 2001,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vAj6j1ngoRoucI7uD2vIRQ--~B/aD0yMDAxO3c9MzAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/433110cf9f928b1f27e41465a8ce0b49.cf.webp",
              "width": 3000,
              "height": 2001,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ge8o_yIBxIO_6lhn.OOO_g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/433110cf9f928b1f27e41465a8ce0b49.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/tempus-shares-jump-strong-preliminary-183532772.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tempus-shares-jump-strong-preliminary-183532772.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "TEM"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": null
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-12T22:45:00+00:00",
    "headline": "3 retail trends to watch in 2026, according to NRF 2026",
    "summary": "The National Retail Federation (NRF) is hosting its Retail's Big Show conference in New York City this week. Attending the event, Yahoo Finance Senior Reporter Brooke DiPalma sat down with KPMG US consumer & retail sector leader Duleep Rodrigo and PwC partner and US consumer markets industry leader Alison Furman to hear how retailers will be employing AI applications and how companies are expected to adjust to the adoption of GLP-1 weight-loss drugs and more active lifestyles by consumers. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Asking for a Trend.",
    "url": "https://finance.yahoo.com/video/3-retail-trends-watch-2026-224500459.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "064588e9-3daa-3043-aa6e-7e0e6776c6cf",
      "content": {
        "id": "064588e9-3daa-3043-aa6e-7e0e6776c6cf",
        "contentType": "VIDEO",
        "title": "3 retail trends to watch in 2026, according to NRF 2026",
        "description": "<p>The National Retail Federation (NRF) is hosting its Retail's Big Show conference in New York City this week.</p>\n<p>Attending the event, Yahoo Finance Senior Reporter <a data-i13n=\"cpos:1;pos:1\" href=\"https://www.yahoo.com/author/brooke-dipalma/\">Brooke DiPalma</a> sat down with KPMG US consumer & retail sector leader Duleep Rodrigo and PwC partner and US consumer markets industry leader Alison Furman to hear how retailers will be employing AI applications and how companies are expected to adjust to the adoption of GLP-1 weight-loss drugs and more active lifestyles by consumers.</p>\n<p>To watch more expert insights and analysis on the latest market action, check out more <a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/videos/series/asking-for-a-trend/\">Asking for a Trend</a>.</p>",
        "summary": "The National Retail Federation (NRF) is hosting its Retail's Big Show conference in New York City this week. Attending the event, Yahoo Finance Senior Reporter Brooke DiPalma sat down with KPMG US consumer & retail sector leader Duleep Rodrigo and PwC partner and US consumer markets industry leader Alison Furman to hear how retailers will be employing AI applications and how companies are expected to adjust to the adoption of GLP-1 weight-loss drugs and more active lifestyles by consumers. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Asking for a Trend.",
        "pubDate": "2026-01-12T22:45:00Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2026-01/8c48f660-f005-11f0-aeb7-1fd78e6dbefe",
          "originalWidth": 4250,
          "originalHeight": 2390,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tMnqNZixVpW010P7QO1SHw--~B/aD0yMzkwO3c9NDI1MDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2026-01/8c48f660-f005-11f0-aeb7-1fd78e6dbefe.cf.webp",
              "width": 4250,
              "height": 2390,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OcryTWcyChhx_H5HhvKXog--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2026-01/8c48f660-f005-11f0-aeb7-1fd78e6dbefe.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/3-retail-trends-watch-2026-224500459.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/3-retail-trends-watch-2026-224500459.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "XLP"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "XLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-12T22:04:00+00:00",
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Find insight on Pfizer, Johnson & Johnson and more in the latest Market Talks covering the health care sector.",
    "url": "https://www.wsj.com/business/health-care-roundup-market-talk-ba4bb526?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "435e338d-d14f-3580-954c-a610acc98c0f",
      "content": {
        "id": "435e338d-d14f-3580-954c-a610acc98c0f",
        "contentType": "STORY",
        "title": "Health Care Roundup: Market Talk",
        "description": "",
        "summary": "Find insight on Pfizer, Johnson & Johnson and more in the latest Market Talks covering the health care sector.",
        "pubDate": "2026-01-12T22:04:00Z",
        "displayTime": "2026-01-12T22:04:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/435e338d-d14f-3580-954c-a610acc98c0f/health-care-roundup-market.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/f2bec8dc98b10078f647d871658f461a",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WrhZrzCfqtmt.BmE13YeQA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/f2bec8dc98b10078f647d871658f461a.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OE1vcNqqSRZ1WIBYKKRlWQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/f2bec8dc98b10078f647d871658f461a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/business/health-care-roundup-market-talk-ba4bb526?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-12T22:00:26+00:00",
    "headline": "UBS Likes Pfizer’s MTSR Obesity Deal but Stays Neutral on PFE",
    "summary": "Pfizer Inc. (NYSE:PFE) is included among the 13 Best Dividend Stocks Paying Over 6%. On January 7, UBS initiated coverage of Pfizer Inc. (NYSE:PFE) with a Neutral rating and a $25 price target. The firm pointed to lingering uncertainty around Pfizer’s revenue outlook, with roughly $15 billion to $20 billion tied to major drugs expected […]",
    "url": "https://finance.yahoo.com/news/ubs-likes-pfizer-mtsr-obesity-220026054.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "856c1609-e3a2-3b35-8c67-3ecc78cc29b8",
      "content": {
        "id": "856c1609-e3a2-3b35-8c67-3ecc78cc29b8",
        "contentType": "STORY",
        "title": "UBS Likes Pfizer’s MTSR Obesity Deal but Stays Neutral on PFE",
        "description": "",
        "summary": "Pfizer Inc. (NYSE:PFE) is included among the 13 Best Dividend Stocks Paying Over 6%. On January 7, UBS initiated coverage of Pfizer Inc. (NYSE:PFE) with a Neutral rating and a $25 price target. The firm pointed to lingering uncertainty around Pfizer’s revenue outlook, with roughly $15 billion to $20 billion tied to major drugs expected […]",
        "pubDate": "2026-01-12T22:00:26Z",
        "displayTime": "2026-01-12T22:00:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "UBS Likes Pfizer’s MTSR Obesity Deal but Stays Neutral on PFE",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UKiv8LHLxutAA7dDIzr_pw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1v0rnd.QZj0de1gLzaNuAg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ubs-likes-pfizer-mtsr-obesity-220026054.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ubs-likes-pfizer-mtsr-obesity-220026054.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-12T21:21:00+00:00",
    "headline": "Expect a Busy Year in Obesity Drugs as New Pills Hit the Market",
    "summary": "Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026’s first half.",
    "url": "https://www.barrons.com/articles/obesity-drugs-pills-fda-ce526357?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "0b802b93-015b-337a-a44d-e51651c9fd69",
      "content": {
        "id": "0b802b93-015b-337a-a44d-e51651c9fd69",
        "contentType": "STORY",
        "title": "Expect a Busy Year in Obesity Drugs as New Pills Hit the Market",
        "description": "",
        "summary": "Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026’s first half.",
        "pubDate": "2026-01-12T21:21:00Z",
        "displayTime": "2026-01-12T21:21:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/0b802b93-015b-337a-a44d-e51651c9fd69/expect-a-busy-year-in-obesity.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/dc1c6f9012998f61fbc4f365deabfe09",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/C9yL9x59djC1XvjyvVAfNQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/dc1c6f9012998f61fbc4f365deabfe09.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oFcwB0B9.gWnduYSZOmDZw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/dc1c6f9012998f61fbc4f365deabfe09.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/obesity-drugs-pills-fda-ce526357?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "RHHBY"
            },
            {
              "symbol": "RHHVF"
            },
            {
              "symbol": "ZLDPY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "ZLDPF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-12T17:18:00+00:00",
    "headline": "JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year",
    "summary": "Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to appease jittery investors.",
    "url": "https://www.biopharmadive.com/news/jpm26-china-biotech-pfizer-obesity-bristol-sarepta-elevidys-sales/809320/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "90d9effa-b4ba-3553-ad33-7f3641f07a91",
      "content": {
        "id": "90d9effa-b4ba-3553-ad33-7f3641f07a91",
        "contentType": "STORY",
        "title": "JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year",
        "description": "",
        "summary": "Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to appease jittery investors.",
        "pubDate": "2026-01-12T17:18:00Z",
        "displayTime": "2026-01-12T17:18:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "BioPharma Dive, an Industry Dive publication",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/U3g5.ulK0vcCqcdyFlYvVw--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DH6ljKWVk5FO27mUzvHUcQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/jpm26-china-biotech-pfizer-obesity-bristol-sarepta-elevidys-sales/809320/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jpm26-us-biotech-sputnik-moment-171800003.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-12T23:42:53+00:00",
    "headline": "Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra",
    "summary": "SAN FRANCISCO, Jan 12 (Reuters) - Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched erectile dysfunction drug ​Viagra in 1998, CEO Albert Bourla said on Monday. Bourla said that even when the drugmaker was ‌negotiating its purchase of weight-loss drugmaker Metsera, initially announced in September 2025, Pfizer did not expect the cash-pay market for obesity drugs ‌currently dominated by Eli Lilly and Co and Novo Nordisk to get s",
    "url": "https://finance.yahoo.com/news/pfizer-ceo-plans-soaring-consumer-234253473.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "602766f8-196d-357d-bbc7-ce8d3f4c59b7",
      "content": {
        "id": "602766f8-196d-357d-bbc7-ce8d3f4c59b7",
        "contentType": "STORY",
        "title": "Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra",
        "description": "",
        "summary": "SAN FRANCISCO, Jan 12 (Reuters) - Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched erectile dysfunction drug ​Viagra in 1998, CEO Albert Bourla said on Monday. Bourla said that even when the drugmaker was ‌negotiating its purchase of weight-loss drugmaker Metsera, initially announced in September 2025, Pfizer did not expect the cash-pay market for obesity drugs ‌currently dominated by Eli Lilly and Co and Novo Nordisk to get s",
        "pubDate": "2026-01-12T23:42:53Z",
        "displayTime": "2026-01-12T23:42:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/abfbaa0700d02a4fa0ed8373a1578b40",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gjpQLHbUDGIigJ7FfcAYGQ--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/abfbaa0700d02a4fa0ed8373a1578b40.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VSJr.Iy5W1dt_2Q4p_VgiQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/abfbaa0700d02a4fa0ed8373a1578b40.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-ceo-plans-soaring-consumer-234253473.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-ceo-plans-soaring-consumer-234253473.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-12T18:35:32+00:00",
    "headline": "Why Tempus AI Stock Jumped on Monday?",
    "summary": "Investors Eye 2026 Guidance as Tempus AI Tops $1.1B in Contract Value",
    "url": "https://finance.yahoo.com/news/tempus-shares-jump-strong-preliminary-183532772.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "499a3594-e9d6-3fd4-93a4-f477fe21e7fd",
      "content": {
        "id": "499a3594-e9d6-3fd4-93a4-f477fe21e7fd",
        "contentType": "STORY",
        "title": "Why Tempus AI Stock Jumped on Monday?",
        "description": "",
        "summary": "Investors Eye 2026 Guidance as Tempus AI Tops $1.1B in Contract Value",
        "pubDate": "2026-01-12T18:35:32Z",
        "displayTime": "2026-01-12T18:35:32Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/433110cf9f928b1f27e41465a8ce0b49",
          "originalWidth": 3000,
          "originalHeight": 2001,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vAj6j1ngoRoucI7uD2vIRQ--~B/aD0yMDAxO3c9MzAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/433110cf9f928b1f27e41465a8ce0b49.cf.webp",
              "width": 3000,
              "height": 2001,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ge8o_yIBxIO_6lhn.OOO_g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/433110cf9f928b1f27e41465a8ce0b49.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/tempus-shares-jump-strong-preliminary-183532772.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tempus-shares-jump-strong-preliminary-183532772.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "TEM"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]